AUSTRALIAN listed cannabis firm Creso Pharma has signed an exclusive commercialisation agreement with Swiss pharma company Doetsch Grether for marketing of Creso's hemp based nutraceutical cannaQIX10 in Switzerland as a food supplement.
An ASX statement announcing the deal said the arrangement "lays the cornerstone for Creso's global commercialisation".
The agreement is for a 10 year period, targeting the largest pharmacy chains in both Switzerland and Leichtenstein.
Although it is one of the largest pharma/OTC and consumer care companies in Switzerland, Doetsch Grether is actually a medium-sized, family-owned company specialising in the distribution of products in the Swiss pharma, OTC and consumer care market, where it has operated since 1899.
CannaQIX10 is described by Creso as a pharma-grade, CBD-based product in packs of 20, 40 and 60 pastilles, or small sweet lozenges.
Designed for direct buccal absorption into the bloodstream, the pastilles are said to work faster and more efficiently than tablets or capsules that need to be swallowed and therefore cope with stomach acid and other absorption and bioavailability challenges.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 17
